Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chris making as good a case as any for investing in Lexaria at a Richmond Club luncheon:
There are soooo many best case scenarios for this company...
Took a tiny nibble at $0.70. (I have no money... XD)
XD ... Yeah - "You got me."
This is what I do on nights and weekends. ;D
Hill Street's Terry Donnelly expounds upon the deal with Lexaria:
Gross...! XD
This is my (conspiracy) theory as well.
I posted a link, a few months back, outlining how big co.s interested in buying smaller companies out had all sorts of trickery they could resort to - behind the curtain, of course - to drive and keep the latter's stock price down.
Bunka says he doesn't understand it... (The market's perceived lack of response.)
We all (I'll speculate) agree we don't understand it... (The price action.)
Gotta say - one has to wonder.
It goes without saying that we must always bear in mind we are discussing a penny stock - i.e., a volatile, unpredictable and readily manipulated class of security - trading on the Canadian exchanges - i.e., a notoriously ill-regulated market, unfortunately.
New manufacturing deal with Hill Street...!
http://www.digitaljournal.com/pr/4392667
Hah! Think more like "mosquito to an elephant"... :\
I hate to admit it, but I'm sooorta rootin' for it to stay here just a tad longer - I have a little powder coming-in next week and would love to nibble some more.
Thanks corky. :)
"The big money is not in the buying or the selling, but in the waiting. [...] The world is full of foolish gamblers and they will not do as well as the patient investors.”
-- Charlie Munger, who's done quite well for himself
Frankly...? Don't care.
Let me know when they've got:
- dosage control, and
- minimized onset time, and
- maximized bioavailability, and
- taste masking, and
- sympathetic (i.e., healthy) absorption, and
- cannabis and nicotine/tobacco and pharma interested in their tech.
I'll pay attention then.
Thanks for sharing Abundance88.
"There will be more [deals]. You just stay tuned."
Love it.
Missed it. :*(
Any interesting questions/answers? (Secrecy around deal terms, why ChrgD+ was a "soft open", etc.)
Yup...!
https://finance.yahoo.com/news/lexaria-bioscience-enters-cbd-beverage-101000282.html
Tough going these days. But this is penny stock land. ("If you can't stand the heat,...") Traders are fickle.
One way or the other though, eventually, the domino that'll make Lexy "too good to ignore" will fall.
My humble $0.02.
"Forest for the trees." ;)
"It's alive!!"
https://chrgd.life/
They are (over)burdened by a ton of regulation restricting what they can sell to whom when and where.
I think this is a tad pessimistic.
"Investors" include institutions and retail. But institutions don't "take flyers"; so, you're left with retail.
Now... Retail investors have a fraction of the cumulative buying power institutions have.
Of that fraction, a fraction is directed to "buy and hold" investment (by retail investors of that inclination).
Of that fraction, a fraction is directed at "buy and hold"ing penny stocks (by retail investors of that inclination).
Of that fraction, a fraction is directed at a given penny stock (by retail investors of whatever inclination).
I'd posit that a fraction of a fraction of a fraction of a fraction of "investors" have indeed taken a flyer on the future, and bought and held (i.e., are holding) shares.
What we aren't seeing, arguably, is "more" of them doing it, yes. But hey - those that have the above-listed attributes - interested in taking a flyer on a bioscience company with little/no revenue, no less - will only ever be so many.
Once something changes about the company (major deal announced, revenue generated, etc.), things will change about the investors. There's absolutely no reason it ought to be the other way around in the case of a co/stock like Lexy.
A theory:
- Altria buys the Nicotine sub.
- Cronos buys the Hemp and/or CanPharm sub(s).
- Chris & co. go forth and prosper with Pharma - where the "real" money (not to mention research) will be anyway eventually. (I.e., Lexy becomes a pharma company/sub, not bothering itself much with nicotine and/or cannabis but with things like Viagra, NSAIDs, etc.)
Basically, I think a number of buyouts are being anticipated/considered (or already on the table), and the challenge is how to structure the deals such that no one entity gets all the IP on an exclusive basis.
Complete conjecture.
"Improved Bioavailability" value-add FTW baby...
Tick... Tock...
Tick... Tock...
Tick... Tock...
https://chrgdlife.com/
If I had $85,000, I'd take this gamble without batting an eyelash.
Altria has a relationship with Cronos.
Altria has a relationship with Lexaria.
Altria will want their stake in Cronos to be as successful as possible, no doubt - just like they want their nicotine business to be successful (obviously).
If they like what they see from Lexy on the nicotine front, I can think of no reason why they wouldn't want to see Cronos leverage the tech to establish some sort of competitive advantage/edge.
Therefore, "Altria - Cronos - Lexaria", methinks.
But... "who knows."
Need... dry... powder... :*(
That's right - we don't want nonayer good time here...! (Give us more news instead! XD)